News

Allon Therapeutics announces completion of patient enrollment in pivotal trial

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced today that it has successfully achieved the enrollment objective of 300 patients in the phase 2/3 pivotal clinical trial evaluating the Company’s lead neuroprotective drug candidate davunetide as a potential treatment for progressive ... Continue reading →

Allon Therapeutics Completes Equity Offering

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC), today announced that it has completed the previously announced public offering of units and common shares resulting in gross proceeds of $4,357,842.50 and a subscription receipt for $1,084,032.50 for a total of $5,441,875 as more particularly ... Continue reading →

Allon granted important U.S. patent for preclinical compound AL-408

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced today that it has been granted an important United States patent covering the composition of matter for the D-isomer of NAP (davunetide). The D-isomer of davunetide is known as AL-408 in the company’s pipeline.  This new patent streng... Continue reading →

Allon Therapeutics Amends Terms of Offering and Prices Offering

VANCOUVER, B.C. – Allon Therapeutics Inc. (“Allon Therapeutics” or the “Company”) (TSX – “NPC”) announced today that, further to its press release dated September 14, 2011,  that GMP Securities L.P. (the “Lead Agent”), on behalf of a syndicate of agents, including Canaccord Genuity Corp. (togethe... Continue reading →

Allon Therapeutics Announces Overnight Marketed Equity Offering

VANCOUVER, B.C. – Allon Therapeutics Inc. (“Allon Therapeutics” or the “Company”) (TSX – “NPC”) is pleased to announce that it has filed today a short form preliminary prospectus in respect of an overnight marketed offering of units (the “Offering”), each unit being comprised of one common share ... Continue reading →

← Older posts Newer posts →